Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
DNADetect
Calgary, Alberta, Canadaresearchgate.net ↗
- Ownership
- Private
- Development stage
- Preclinical
01
Overview
DNADetect has developed a cutting-edge nanoscale biosensor that leverages RNA aptamers and DNA origami to rapidly pinpoint neurovascular damage. The technology appears to be in the prototype or pre-commercialization phase, with no published clinical results yet.[2]
- Therapeutic areas
- Neurology
- Modalities
- Biosensors (nanoscale biosensors using RNA aptamers and DNA origami)[2]
- Industry
- Molecular Diagnostics
02
Partnerships
Not specified; possible academic or research collaborations implied by the nature of the technology but not explicitly listed.
Beyond the preview
Go deeper on DNADetect.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DNADetect.